Trials / Recruiting
RecruitingNCT06927687
Study of ZG005 in Patients With Advanced Solid Tumors
A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ZG005 for Injection | Recommended Phase 2 Dose (RP2D) of ZG005(20 mg/kg), intravenous infusion, once every 3 weeks. |
Timeline
- Start date
- 2025-06-13
- Primary completion
- 2027-05-01
- Completion
- 2027-06-01
- First posted
- 2025-04-15
- Last updated
- 2026-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06927687. Inclusion in this directory is not an endorsement.